Ocugen Inc
NASDAQ:OCGN
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 56 full-time employees. The company went IPO on 2014-12-03. The firm's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The company is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 56 full-time employees. The company went IPO on 2014-12-03. The firm's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The company is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.
Pipeline milestones: Ocugen expects to start a rolling BLA for OCU400 in Q3 2026, report OCU400 Phase III top-line data in Q1 2027 and target commercialization in 2027.
OCU400 enrollment: Phase III liMeliGhT enrollment is complete; management reiterated confidence in delivering top-line 12‑month data on schedule.
OCU410 (GA) interim data: Preliminary 12‑month data showed a 46% reduction in lesion growth (medium+high dose) vs control (p = 0.05, cohort n=23) and a 50% responder rate; full Phase II data expected this month and Phase III planned in 2026.
OCU410ST (Stargardt): OCU410ST targets many ABCA4 mutations; Phase II/III top line data anticipated in Q2 2027 and a prior Phase I publication supports safety/tolerability and potential efficacy.
Finance / runway: Cash and equivalents fund operations into Q4 2026 (including a $22.5M registered direct offering); full exercise of $30M in outstanding warrants would extend runway into Q2 2027.
Leadership & ops: Key commercial and operations hires made in 2025 to support late-stage development and anticipated commercialization.
Regulatory positioning: EMA agreed U.S. single‑trial data can support a European filing for OCU410ST; company is pursuing EZ (ellipsoid zone) as an exploratory/secondary structural endpoint across trials.
